Camrelizumab Combined With Apatinib for Recurrent Resistant GTN (GTN)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04047017 |
Recruitment Status :
Completed
First Posted : August 6, 2019
Last Update Posted : July 30, 2021
|
Sponsor:
Peking Union Medical College Hospital
Information provided by (Responsible Party):
xiang yang, Peking Union Medical College Hospital
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | August 4, 2019 | ||||
First Posted Date ICMJE | August 6, 2019 | ||||
Last Update Posted Date | July 30, 2021 | ||||
Actual Study Start Date ICMJE | August 8, 2019 | ||||
Actual Primary Completion Date | March 18, 2021 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
ORR(objective response rate) [ Time Frame: Up to one years ] the proportion of patients with complete or partial response according to serum hCG level
|
||||
Original Primary Outcome Measures ICMJE |
PFS(progression free survival) [ Time Frame: Up to two years ] the time from randomization until objective tumor progression or death
|
||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE |
|
||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Camrelizumab Combined With Apatinib for Recurrent Resistant GTN | ||||
Official Title ICMJE | Camrelizumab Combined With Apatinib for Recurrent Resistant Gestational Trophoblastic Neoplasia: a Phase 2, Single-arm, Prospective Study | ||||
Brief Summary | This study is to evaluate the efficacy and safety of camrelizumab plus apatinib in patients with high-risk chemo-refractory or relapsed GTN. | ||||
Detailed Description | Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2. Novel immunotherapy using the immune checkpoint inhibitors such as anti-PD-1 antibody has received much attention. Camrelizumab as one of the anti-PD-1 drug have impressive clinical activity. | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 2 | ||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||
Condition ICMJE | Gestational Trophoblastic Disease | ||||
Intervention ICMJE |
|
||||
Study Arms ICMJE | Experimental: Test group
Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd
Interventions:
|
||||
Publications * | Cheng H, Zong L, Kong Y, Wang X, Gu Y, Cang W, Zhao J, Wan X, Yang J, Xiang Y. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2021 Nov;22(11):1609-1617. doi: 10.1016/S1470-2045(21)00460-5. Epub 2021 Oct 5. | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Actual Enrollment ICMJE |
20 | ||||
Original Estimated Enrollment ICMJE | Same as current | ||||
Actual Study Completion Date ICMJE | May 15, 2021 | ||||
Actual Primary Completion Date | March 18, 2021 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years to 70 Years (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | China | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT04047017 | ||||
Other Study ID Numbers ICMJE | OBU-GTN-MUL-IIT-SHR1210-APA | ||||
Has Data Monitoring Committee | Not Provided | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Current Responsible Party | xiang yang, Peking Union Medical College Hospital | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor ICMJE | Peking Union Medical College Hospital | ||||
Original Study Sponsor ICMJE | Same as current | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE | Not Provided | ||||
PRS Account | Peking Union Medical College Hospital | ||||
Verification Date | July 2021 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |